Results of induction chemotherapy followed by three-dimensional conformal radiotherapy and con current weekly paclitaxel for stage Ⅲ non-small cell lung cancer

( views:319, downloads:0 )
WANG Wei-hua(Department of Radiation Oncology,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Guangzhou 510060,China)
BAO Yong(Department of Radiation Oncology,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Guangzhou 510060,China)
CHEN Ming(Department of Radiation Oncology,Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Guangzhou 510060,China)
LI Kai-xin()
XU Guang-chuan()
Journal Title:
Volume 17, Issue 04, 2008
Key Word:
Carcinoma,non-small cell lung/radiotherapy;Carcinoma,non-small cell lung/chemotherapy;Treatment outcome

Abstract: Objective To evaluate the toxicity and efficacy of induction chemotherapy(ICT)followed by three-dimensional conformal radiotherapy(3 DCRT)plus concurrent weekly paclitaxel for inoperable non-small cell lung cancer(NSCLC). Methods Patients with stage Ⅲ NSCLC in favorable conditions were treated with 2 to 4 cycles of carboplatin(AUC=5-6,d1)combined with paclitaxel(175 mg/m2,d1),then followed by weekly paclitaxel(40 mg/m2)and concurrent 3DCRT within 3-4 weeks.The prescription dose of radiotherapy was given as high as possible while total lung V20≤31% and total dose of the spinal cord ≤50 Gy. Results ICT was well tolerated.During the concurrent chemoradiotherapy,the treatment of 4 patients was ended ahead of the schedule because of severe pulmonary and cardiac toxicities:the treatment of 2 patients was delayed for 7 and 12 days because of fatigue.Leucopenia(33/56)was in grade 1-2 except 1 patient in grade 3.Lymphocytopenia was severe(54/56,42 in grade 3).Three patients developed grade 3 acute radiation-induced esophagitis.and 3 developed grade 3-4 radiation-induced pneumonitis.There was one patients each who developed grade 2,3,and 4 late esophageal damage,respectively.Nine developed grade 2 pulmonary fibrosis.The overall response rate was 69.7%.The 1-year overall survival rate was 72.3%.The 1-year local progression-free survival rate was 62.7%. Conclusions The schedule of ICT followed by weekly paclitaxel and concurrent 3DCRT can be well tolerated by most of the favorable patients with stageⅢ NSCLC.and the toxicity is tolerable. Results of this study are encouraging, though long-term results should be followed up.

  • [1]Non-small cell lung cancer collaborative group.Chemotherapy in non-small cell lung cancer.Meta-analysis using updated data on individual patients from 52 randomized clinical trials.Br Med J,1995,311:899-909
  • [2]Pritchard RS,Anthony SP.Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced non-small-cell lung Cancer.A meta-analysis.Ann Intern Med,1996,125:723-729.
  • [3]Furnse K,Fukuoka M,Kawahara M,et al.Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin,vindesine,and cisplatin in unresectable stage Ⅲ nonsmall-cell lung cancer.J Clin Oncol,1999,17:2692-2699.
  • [4]Curran WJ,Scott cB,Langer JL,ct al.Long-term benefit is observed in a phase Ⅲ comparison of sequential vs.concurrent chemoradiation therapy for patients with unresectable stage Ⅲ NSCLC.Proc Am Soc Clin Oncol,2003,22:621.
  • [5]Vokes EE,Herndon JE,Kelley MJ,et al.Induction chemotherapy followed by concomitant chemoradiotherapy(CT/XRT)versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer(NSCLC):initial analysis of a randomized phase Ⅲ tfial.Proc Am Soc Clin Oncol,2004,22:7005.
  • [6]Belani CP,Choy H,Bonomi P,et al.Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced nonsmall-cell lung cancer:arandomized phase Ⅱ locally advanced multi-modality protocol.J Clin Oncol,2005,23:5883-5891.
  • [7]Cater DL,KellerAM,Tolley RC,et al.A randomized phase Ⅲtrial of combined paclitaxel,carboplatin,and radiation therapy followed by either weekly paclitaxel observation in patients with stage Ⅲnon-small cell lung cancer.Proc Am Soc Clin Oncol,2004,22:7076a.
  • [8]Kelly K,Crowley J,Bunn PA et al.A randomized phase Ⅲtrial of paclitaxel plus carboplatin(PC)versus vinorelbine plus cisplatin (VC)in untreated advanced non-small cell lung cancer (NSCLC):a Southwest Oncology Group(SWOG)trial.Proc AmSoc Clin Oncol,1999,18:1777a.
  • [9]Fisher MD,D'Orazio A.Phase Ⅱ and Ⅲ trials:comparison of four chemotherapy regimens in advanced non small-cell lung cancer(ECOG 1594).Clin Lung Cancer,2000,2:21-22.
  • [10]Giraud P,Antoine M,Larrouy A,et al,Evaluation of microscopic tumor extension in non-small cell lung cancer for three-dimensional conformal radiotherapy planning.Int J Radiat Oncol Biol Phys,2000,48:1015-1024.
  • [11]Komaki R,Scott CB,Sause WT,et al.Induction cisplatin/vinblastine and irradiation therapy vs.irradiation therapy in unresectable squamous cell lung cancer:failure patterns by cell type in RTOG88-08/ECOG 4588.Int J Radiat Oncol Biol Phys.1997,39:537-544.
  • [12]Schaake-Koning C,Van Den Bogaert W,Dalesio O,et al.Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall cell lung cancer.N Engl J Med,1992,326:524-530.
  • [13]Choy H,Rodriguez FF,Koester S,et al.Investigation of Taxol as apotential radiation sensitizer.Cancer,1993,71:3774-3778.
  • [14]Manfredi JJ,Parness J,Horwitz SB.Taxol binds to cellular micro.tubles.J Cell Biol,1982,94:688-696.
  • [15]Safran H,King TP,Choy H,et al.p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung cancer.Cancer,1996,78:1203-1210.
  • [16]Chen M,Wu SX,Chen YY,et al.Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma-outcomes of a phase Ⅰ trial.Am J Clin Oncol.2004,27:481-484
  • [17]陈明,陈媛媛,包勇,等.诱导化疗和后程加速超分割放射治疗局部晚期非小细胞肺癌的临床Ⅰ/Ⅱ期试验的结果.中华放射肿瘤学杂志,2005,14:249-252.
  • [18]Carcereny E,Casas F,Vinolas N,et al.Radiotherapy(RT)with concurrent paclitaxel plus carboplatin and placlitaxel administered as induction andconsolidation chemotherapy(CT)in locally advanccd non small cell lung cancer(NSCLC):phase Ⅱ study.Lung Cancer,2005,49 Suppl 2:S167.
  • [19]Socinski MA,Halle JS,Morris DE,et al.Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy.Lung Cancer,2003,41 Suppl 2:S239.
  • [20]Hayman JA,Martel MK,Ten Haken R,et al.Dose escalation in non-small-cell lung cancer using three dimensional conformal radiation therapy:update of a phase Ⅰ trial.J Clin Oncol,2001,19:127-136.
  • [21]Martel MK,Ten Haten RK,Hazuka MB,et al.Estimation of tumor control probability model parameters from 32 d dose distributions of non-small cell lung cancer patients.Lung Cancer,1999,24:31-37.
  • [22]Swann RS,Machtay M,Komaki R,et al.Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC:an RTOG secondary analysis.Proc Am Soc Clin Oncol,2005.24:7061a.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615